Portal de investigación
Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients
Fecha de publicación:
Fecha Ahead of Print:
Grupos y Plataformas de I+D+i
Abstract
Neurofilament light chain protein (NfL) levels reflect neuronal damage in several neurological diseases and have been proposed as a possible biomarker. Plasma extracellular vesicles (EVs) could play an important role as mediators of the inflammatory changes associated with inducing minimal hepatic encephalopathy (MHE) in cirrhotic patients. This study investigated the association of NfL levels in plasma and EVs with the presence of MHE in cirrhotic patients, and with responses to rifaximin treatment. The NfL levels in plasma and EVs were assessed in 71 patients with liver cirrhosis (40 with MHE and 31 without MHE) and 26 controls. A total of 31 patients with MHE received rifaximin treatment. We examined changes in NfL levels in plasma and EVs before and after 6 months of rifaximin treatment. The NfL measures were correlated with cognitive alterations and plasma inflammatory cytokines. MHE patients showed increased plasma levels of NfL, which were reverted after rifaximin treatment in patients who responded to treatment. The NfL content in EVs also showed a reversal pattern in MHE patients treated with rifaximin. In multivariable analyses, NfL levels were independently associated with the presence of MHE. We also showed that patients with high levels of both ammonia and fractalkine had significantly higher NfL levels than patients with low levels of least one of these parameters. Rifaximin treatment in MHE patients showed promising results in improving axonal damage, suggesting that rifaximin may have therapeutic benefits against disease progression in MHE.
Datos de la publicación
- ISSN/ISSNe:
- 1661-6596, 1422-0067
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 37834174
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES MDPI AG
Citas Recibidas en Web of Science: 6
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- neurofilament light chain protein; extracellular vesicles; minimal hepatic encephalopathy; rifaximin; inflammation; ammonia
Financiación
Proyectos y Estudios Clínicos
Caracterización de las alteraciones neurológicas y cerebrales en pacientes con encefalopatía hepática mínima. contribución de la inflamación. Implicaciones diagnósticas y terapéuticas.
Investigador Principal: MARÍA DEL CARMEN MONTOLIU FÉLIX
GRISOLIAP/2019/003 . CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO . 2019
ESTUDIO DE LAS ALTERACIONES NEUROLÓGICAS, CEREBRALES Y BIOQUÍMICAS EN PACIENTES CON ENFERMEDAD GRASA DEL HÍGADO. MECANISMOS MOLECULARES Y CELULARES.
Investigador Principal: FRANC CASANOVA FERRER
ACIF/2019/232 . CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO
Cita
Fiorillo A,Gallego JJ,Casanova F,Urios A,Ballester MP,San Miguel T,Megías J,Kosenko E,Tosca J,Rios MP,Escudero D,Montoliu C. Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients. Int. J. Mol. Sci. 2023. 24. (19):14727. IF:4,900. (1).
Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients. Fiorillo A, Gallego JJ, Casanova F, Urios A, Ballester MP, San Miguel T, Megías J et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023 octubre 01. 24 (19):DOI:10.3390/ijms241914727. PMID:37834174.
